TEE
GALT icon

Tibra Equities Europe’s Galectin Therapeutics GALT Stock Holding History

Tibra Equities Europe’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-98,700
Closed -$316K – 103
2021
Q2 		$316K Buy
+98,700
New +$351K 0.1% 156
2019
Q2 		– Sell
-72,685
Closed -$371K – 318
2019
Q1 		$371K Buy
+72,685
New +$349K 0.04% 300
2018
Q2 		– Sell
-63,414
Closed -$301K – 143
2018
Q1 		$301K Buy
+63,414
New +$295K 0.05% 169

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Tibra Equities Europe's GALT Position: Q3 2021 in Review

Tibra Equities Europe sold out of Galectin Therapeutics (GALT) in Q3 2021, closing a stake of 98,700 shares — an estimated $316K sold.

Tibra Equities Europe first reported a position in GALT in Q1 2018 and held it in 3 quarters. The position peaked at $371K in Q1 2019. 70 funds tracked by Wall St. Rank hold GALT as of Q3 2021.

  • Tibra Equities Europe reported no remaining Galectin Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 98,700 Galectin Therapeutics shares in Q3 2021, an estimated $316K.
  • Tibra Equities Europe first reported a position in Galectin Therapeutics in Q1 2018 and held it in 3 quarters.
  • Tibra Equities Europe's Galectin Therapeutics position peaked at $371K in Q1 2019.
  • 70 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.